Marinus Pharmaceuticals has found $21 million in Series C financing from the venture outfit Domain Associates and a pharma-focused unit of the Russian investment firm Rusnano. The funding backs further development of the Branford, CT-based developer's nanotechnology-formulated version of the steroid Ganaxolone, which the company licensed from Purdue Pharma, for multiple CNS ailments such as epilepsy, post-traumatic stress disorder, and fragile-X syndrome. Release